NCT03625778View on ClinicalTrials.gov

A Study to Assess Safety, Tolerability, and Pharmacokinetics of MEDI0382 in Non-diabetic Obese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

August 14, 2018

Primary Completion Date

August 25, 2019

Study Completion Date

August 25, 2019

Conditions
Obesity
Interventions
DRUG

MEDI0382

MEDI0382 will be administered subcutaneously daily according to the MEDI0382 cohorts.

DRUG

Placebo

Placebo will be administered subcutaneously daily according to the Placebo cohorts.

Trial Locations (2)

32117

Research Site, Daytona Beach

75247

Research Site, Dallas

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
lead

MedImmune LLC

INDUSTRY